---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058730"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:17:01.430356+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CalciMedica Q1 net income $0.1M; CARPO Phase 2b enrollment completed; cash into 2H 2025

## Summary
- Net income of $0.1M ($0.01/share) driven by $5.6M non-cash gain on warrant liability, offsetting $5.8M operating loss.
- Cash & equivalents $25.7M as of March 31, 2024; expected to fund operations into second half of 2025.
- Phase 2b CARPO trial (Auxora in acute pancreatitis) fully enrolled at 216 patients; topline data expected in Q2 2024.
- Phase 2 KOURAGE trial (Auxora in severe AKI with respiratory failure) cleared by FDA; first patient enrollment expected Q2 2024.
- Private placement raised up to ~$54M ($20.4M upfront, ~$33.1M warrants) to support ongoing and planned trials.

## SEC filing metadata
- accession: 0000950170-24-058730
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000095017024058730/0000950170-24-058730-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000095017024058730/calc-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058730
- JSON: https://secwatch.observer/filing/0000950170-24-058730.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058730.txt

## Key facts
- Earnings Releases
  CalciMedica, Inc. reported the first quarter ended March 31, 2024 results: net income $0.1 million, EPS $0.01 per share (basic and diluted).
  - Period: the first quarter ended March 31, 2024
  - Net income: $0.1 million
  - EPS: $0.01 per share (basic and diluted)
  - Result: reported results
  source text: With the impact of a $5.6 million non-cash gain from the fair value adjustment of the warrant liability, net income was $0.1 million, or $0.01 per share (basic and diluted) for the three months March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1534133/000095017024058730/0000950170-24-058730-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.